<h4>Introduction</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are therapies for type 2 diabetes whose use expanded sharply after semaglutide's 2021 approval for obesity. This evidence concerns the gene GLP1R and obesity disorder.